Association Between $T_2^*$ Relaxation Times Derived From Ultrashort Echo Time MRI and Symptoms During Exercise Therapy for Patellar Tendinopathy: A Large Prospective Study

Stephan J. Breda, MD,1,2 Robert-Jan de Vos, MD, PhD,2 Dirk H. J. Poot, PhD,1 Gabriel P. Krestin, MD, PhD,1 Juan A. Hernandez-Tamames, PhD,1 and Edwin H. G. Oei, MD, PhD1*

Background: Exercise therapy is considered preferential treatment for patellar tendinopathy (PT). However, there is conflicting evidence for structural patellar tendon adaptation in response to exercise therapy and its association with symptoms is weak.

Purpose: To assess the association between 1) $T_2^*$ relaxation times and symptom severity; 2) baseline $T_2^*$ and clinical outcome; and 3) longitudinal $T_2^*$ changes and clinical outcome in athletes with PT performing exercise therapy.

Study Type: Randomized controlled clinical trial.

Subjects: Seventy-six athletes (18–35 years) with clinically diagnosed and ultrasound-confirmed PT.

Field strength/Sequence: 3D gradient echo sequence (3.0 T).

Assessment: Patients were enrolled in a randomized trial of progressive tendon-loading exercises (PTLE) versus eccentric exercise therapy (EET). Symptoms were assessed using the Victorian Institute of Sports Assessment (VISA-P) questionnaire. 3D-Ultrasound echo time (UTE)-MRI was acquired at baseline, 12 and 24 weeks. Voxel-wise $T_2^*$ relaxation times were quantified using mono-exponential and bi-exponential models. $T_2^*$ analysis was performed in three patellar tendon tissue compartments representing: aligned collagen, degenerative tissue, and interface.

Statistical Tests: Adjusted general linear, mixed-linear models, and generalized estimating equations.

Results: We included 76 patients with PT (58 men, mean age 24 ± 4 years); 38 in the PTLE-group and 38 in the EET-group, of which 57 subjects remained eligible for analysis. $T_2^*$ relaxation times were significantly associated with VISA-P in degenerative and interface tissues of the patellar tendon. No association was found between baseline $T_2^*$ and VISA-P after 24 weeks ($P > 0.29$). The estimated mean $T_2^*$ in degenerative tissue decreased from 14 msec (95%CI: 12–16) at baseline to 13 msec (95%CI: 11–15) at 12 weeks and to 13 msec (95%CI: 10–15) at 24 weeks. The significant decrease in $T_2^*$ from baseline to 24 weeks was associated with improved clinical outcome.

Data Conclusion: Tissue-specific $T_2^*$ relaxation times, identified with 3D-UTE-MRI, decreased significantly in athletes with patellar tendinopathy performing exercise therapy and this decrease was associated with improved clinical outcome.

Evidence Level: 1

Technical Efficacy: Stage 4

Introduction

Patellar tendinopathy (PT) is a common disorder due to tendon overuse injury in athletes.1 PT is diagnosed, based on localized pain at the attachment of the patellar tendon to the patellar bone.2 Symptoms occur with tendon loading, such as jumping, landing, and cutting in sports activities and...
activities of daily living, or physically demanding work.\textsuperscript{3,4} Symptoms from PT can be assessed using the validated Victorian Institute of Sports Assessment (VISA-P) questionnaire, with an outcome ranging from 0 to 100 points. A score of 100 indicates no pain, maximum function and unrestricted ability to play sports.\textsuperscript{5} Conservative treatment of PT consists of exercise therapy and is focused on increasing the tendon’s capacity to tolerate load.\textsuperscript{6}

The pathophysiology of PT is largely unknown but involves characteristic degenerative changes at the latter stages.\textsuperscript{7} The hierarchical architecture of the patellar tendon normally consists of parallel ordered collagen fibers and ground substance.\textsuperscript{8} Proteoglycans are composed of multiple glycosaminoglycan chains that are attached to a protein core and are found in the extracellular matrix of tendons.\textsuperscript{9} Highly negatively charged proteoglycans attract water and contribute to compressive resistance within the tissue.\textsuperscript{10} In tendinopathy, there is an increase in cellularity and ground substance volume.\textsuperscript{11} Exercise therapy is assumed to reverse this degenerative cascade.\textsuperscript{12} However, there is conflicting evidence that exercise therapy results in structural adaptation measured with clinically available imaging modalities (eg, ultrasound and MRI).\textsuperscript{13} Although the correlation between imaging outcomes and clinical outcomes remains unclear, the glycosaminoglycan content from tendon biopsies correlates well with tendon pain.\textsuperscript{13,14}

Imaging of tendons using MRI with conventional pulse sequences is typically limited by the fast free induction decay of collagen, commonly only visualizing increased signal intensity in the proximal patellar tendon, which may reflect increased water content.\textsuperscript{15} Strong spin–spin interactions usually lead to undetectable signal from short $T_2^*$ relaxation components, such as collagen.\textsuperscript{16}

Ultrashort echo time (UTE) MRI facilitates the detection of signal from short $T_2^*$ tissues such as tendons, which can be used to infer tendon hydration state by voxel-wise $T_2^*$ quantification.\textsuperscript{17} $T_2^*$ analysis reflects signal from protons in different water pools within the patellar tendon, consisting of collagen-bound water pools (shorter $T_2^*$ relaxation times) and free water pools (longer $T_2^*$ relaxation times).\textsuperscript{18} While mono-exponential $T_2^*$ fitting models have shown the best reliability, bi-exponential models allow differentiating voxels in highly organized collagen compartments from degenerative tissue compartments within the patellar tendon.\textsuperscript{19,20}

Previous studies on UTE in tendinopathy have consistently shown increased $T_2^*$ relaxation times.\textsuperscript{21,22} However, quantification of $T_2^*$ changes in PT within specific tissue compartments has not been performed. Moreover, associations with symptoms have not been studied. We hypothesized that temporal changes in $T_2^*$ can be detected using UTE-MRI and might be associated with clinical outcome in athletes with patellar tendinopathy performing exercise therapy.

The first aim of this study was to investigate the association between $T_2^*$ relaxation times within different tissue compartments of the patellar tendon and symptom severity. The second aim was to investigate the association between baseline $T_2^*$ and clinical outcome after exercise therapy. The third aim was to evaluate the association between longitudinal $T_2^*$ changes and changes in severity of symptoms in athletes with PT.

**Materials and Methods**

**Study Participants**

Ethical approval was obtained by the institutional review board and all participants provided written informed consent. Participants enrolled in the JUMPER-study, a randomized controlled trial investigating the effect of progressive tendon-loading exercises (PTLE) vs. eccentric exercise therapy (EET) for PT (ClinicalTrials.gov ID: NCT02938143). Inclusion criteria were age 18–35 years; history of knee pain in the patellar tendon region associated with training and competition; playing sports ≥3 times a week before injury onset; tenderness on palpation of the proximal patellar tendon; structural tendon changes on grayscale ultrasound and/or increased tendon vascularity on power Doppler; Victorian Institute of Sports Assessment (VISA-P) score < 80/100. Exclusion criteria are presented in the trial register. Activity level was measured using the Cincinnati Sports Activity Scale (CSAS).\textsuperscript{23}

**Inclusion Protocol**

After an initial screening of online applications from study advertisements, potentially eligible athletes were invited to our hospital for medical history taking and physical examination performed by one sports physician (R.V.) with 10 years’ experience. Subsequently, grayscale ultrasound (including anteroposterior tendon thickness and the presence of hypoechoic regions, tendon calcifications and erosions of the inferior patellar border) and power Doppler ultrasound (PDUS) were performed by the main investigator, a radiologist-in-training with 5 years’ experience (S.B.) under supervision of a senior musculoskeletal radiologist with 16 years’ experience (E.O.) to confirm the clinical diagnosis PT. Ultrasound was regarded conclusive for PT when structural changes to normal parallel ordered collagen fibers and/or hypoechoic changes and/or tendon thickening (anterior–posterior diameter > 6 mm) were confirmed and/or presence of intratendinous Doppler flow was detected on PDUS.\textsuperscript{24}

**Interventions**

The intervention group performed progressive tendon-loading exercises (PTLE) within limits of acceptable pain, consisting of four consecutive stages (isometric, isotonic, plyometric, and sport-specific exercises).\textsuperscript{3} The control group performed usual care eccentric exercise therapy (EET), which typically provokes substantial pain.\textsuperscript{25} Centralized computer-based randomization was performed in a 1:1 ratio to PTLE or EET, using computer-generated block randomization with a variable block size ranging from 4 to 10. Patients in both study arms were also instructed to perform exercises targeting risk factors for PT. All patients received detailed advice and education on tendon care. Modification of pain-provoking athletic activities was advised for at least 4 weeks and we advised to perform (sports)
activities within the limits of acceptable pain (pain score ≤ 3 points on a scale 0–10). Details regarding these therapeutic interventions are published elsewhere.26 The main investigator (S.B.) was blinded for the allocated treatment during the entire period of data collection.

**Outcomes**

Clinical and imaging outcomes were collected at baseline, 12 and 24 weeks by the main investigator (S.B.). Patients were included in the primary analysis when there was at least one follow-up measurement available.

**Clinical Outcome**

Symptom severity was assessed using the validated Victorian Institute of Sports Assessment (VISA-P) questionnaire prior to image acquisition at every visit.9 The main investigator was blinded for VISA-P scores at the time of image acquisition and analysis.

**Image Acquisition**

Imaging was performed at 3.0 T (Discovery MR750, GE Healthcare, Waukesha, WI, USA) using a 16-channel flexible coil (NeoCoil, Pewaukee, WI, USA) and a fixation device. The knee was positioned in 30° flexion, using a cylindrical tube and foam padding.19

Using a research prototype 3D-UTE-Cones sequence (GE Healthcare), 16 echoes (0.032, 0.49, 0.97, 2.92, 4.87, 6.82, 8.77, 10.72, 12.67, 14.62, 16.57, 18.52, 20.47, 22.42, 24.37, 26.32 msec) were acquired using four multi-echo sequences with a constant repetition time of 83.4 msec.27 The axial 3D-UTE-Cones sequence parameters were acquisition time = 13:15 minutes per multiecho sequence, field-of-view (FOV) = 15 cm, matrix size = 252 × 252, voxel size 0.6 × 0.6 × 1.5 mm³, number of slices = 60, number of excitations (NEX) = 1, bandwidth 125 kHz, flip angle = 17°, and two excitations per fat saturation. Echoes were scanned in interleaved order using four fat saturated multiecho UTE-acquisitions with a total scan time of 53 minutes. The full acquisition protocol is described elsewhere.19 This final protocol was implemented after changing our previously designed image protocol that consisted of seven single echo acquisitions and one multiecho acquisition in the coronal oblique plane without fat saturation (data not included), in order to increase SNR for T₂° quantification.

**Image Preparation**

Image registration was performed to facilitate spatial one-to-one mapping of voxels across longitudinal UTE-acquisitions, using in-house developed tools (Elastix v.4.8, Rotterdam, The Netherlands) and Matlab software (R2015b; TheMathWorks, Natick, MA, USA).28 First, rigid registration was performed on the entire knee volume, which corrected for rotation and translation between multiecho acquisitions and examinations from baseline and follow-up visits. Second, groupwise nonlinear refinement registration was performed on a volume of interest drawn on three orthogonal views, including only the anterior knee part including the patellar tendon.29

**Image Analysis**

Image analysis was performed by the main investigator, a radiologist-in-training with 5 years’ experience (S.B.) under supervision of a postdoctoral researcher specialized in image analysis with 14 years’ experience (D.P.) using an in-house developed Matlab script. For quantitative T₂° analysis, mono-exponential and bi-exponential models were fitted to registered UTE-images, using maximum likelihood estimation incorporating the Rician noise model.20,30 The initial step after fitting the data was to manually segment the outer margins of the patellar tendon on 10 consecutive slices covering the proximal patellar tendon, as described elsewhere.19

Second, the T₂° data within this mask were categorized into three groups, by selecting voxels based on the average over visits of the percentage of short T₂° components from the bi-exponential model (0%–30%, 30%–60%, and 60%–100% short T₂°).19 These three subregions that together spanned the manually drawn mask represented: 1) mostly short T₂° (60%–100% short), 2) mostly long T₂° (0%–30% short), and 3) an interface that separated the two (30%–60% short). The subregions were considered to represent aligned collagen, degenerative tissue, and an interface, respectively and were based on histogram analysis of the T₂° frequency distribution in previous work.19 Finally, the corresponding mono-exponential T₂° relaxation times were used, in these selected voxel groups that were constant over visits, to calculate T₂° relaxation times for each voxel group (patellar tendon subregion) accordingly. Thus, the selected voxel groups that delineated the regions of interest used for analysis were defined on the baseline scans and propagated to follow-up scans to assess temporal changes in T₂° on subsequent scans (after 12 weeks and 24 weeks). The mono-exponential T₂° relaxation times were fitted voxel-wisely in the entire registered scan volume from three separate visits.

**Statistical Analysis**

Normality of data was assessed using the Shapiro–Wilk test and homogeneity of variances was tested using the Levene test. Associations between T₂° relaxation times and VISA-P score were assessed using multiple linear regression analyses. Adjusted general linear models were used to assess associations between baseline T₂° and clinical outcome after 24 weeks. Longitudinal data were analyzed using adjusted generalized estimating equations (GEE) models, to estimate population-averaged effects. Whole group analyses were performed and between-group differences in relation to the time course of the dependent variables were evaluated using an interaction term “study arm”visit” in the GEE model, where the visit defined baseline, 12 weeks or 24 weeks. Bonferroni corrections were applied in the GEE-models for the following comparisons: 1) baseline vs. 12 weeks, 2) 12 weeks vs. 24 weeks, and 3) baseline vs. 24 weeks. Associations with clinical outcome were evaluated using adjusted mixed linear models. All models were adjusted for predefined potential confounding factors, including age, sex, BMI, CSAS, and symptom duration. All analyses were performed following an intention-to-treat principle. Imputation of missing data was not performed. Instead, posthoc sensitivity analyses using the last observation carried forward (LOCF) approach were performed when the amount of missing data exceeded 5% of the total number of observations.31 Statistical analysis was performed using IBM SPSS.
software version 25 (IBM Corp., Armonk, NY, USA). Statistical significance was defined as a $P$-value < 0.05.

Results

Study Population
Athletes were consecutively enrolled between January 2017 and June 2019. A total of 76 included athletes (58 men, mean age 24 ± 4 years) with clinically diagnosed and ultrasound-confirmed PT were included of which 38 were randomized to PTLE and 38 to EET (Fig. 1). Due to a change in the MR acquisition protocol during the study period, 11 subjects were missing for $T_2^*$ analysis. Furthermore, eight subjects could not be included in the primary analysis due to missing data. Demographic characteristics of the study population are listed in Table 1.

Clinical Outcome
Among all athletes, the estimated mean VISA-P score improved significantly from 57 (95% CI: 53–61) at baseline to 72 (95% CI: 67–76) at 12 weeks and 80 (95% CI: 76–84) at 24 weeks follow-up. In the PTLE group, the estimated mean VISA-P score improved significantly from 56 (95% CI: 52–61) at baseline to 84 (95% CI: 79–89) at 24 weeks and in the EET-group it improved significantly from 57 (95% CI: 53–62) to 75 (95% CI: 69–82). The parameter estimate for the “study arm × visit” interaction using GEE was statistically significant. The homogeneity of variance assumption was not violated ($P = 0.59$). The significant adjusted mean between-group difference of the VISA-P score at 24 weeks was 9 points (95% CI: 1–16), in favor of the PTLE group, indicating an improved clinical outcome in athletes performing progressive tendon-loading exercises (PTLE).26

FIGURE 1: The consort flow diagram. PT = patellar tendinopathy; VISA-P = Victorian Institute of Sports Assessment questionnaire for patellar tendons.
### TABLE 1. Baseline Characteristics

| Characteristics                                          | Whole group  | PTLE Group | EET Group |
|----------------------------------------------------------|--------------|------------|-----------|
|                                                          | \((n = 76)\) | \((n = 38)\) | \((n = 38)\) |
| Age, mean (SD), years                                    | 24 (3.8)     | 24 (3.5)   | 24 (4.2)  |
| Sex, male                                                | 58 (76)      | 31 (82)    | 27 (71)   |
| BMI, mean (SD)                                           | 23.9 (2.9)   | 23.8 (2.5) | 24.1 (3.2) |
| Symptom duration, median [IQR], weeks                    | 104 [43–208] | 119 [64–273]| 78 [40–169] |
| VISA-P score, mean (SD)                                  | 55 (13.1)    | 55 (13.1)  | 56 (13.2) |
| Sports Activity Scale (CSAS) prior to onset of PT        |              |            |           |
| Level I (4 days/week–7 days/week)                        |              |            |           |
| 100                                                      | 17 (22)      | 10 (26)    | 7 (18)    |
| 95                                                       | 0 (0)        | 0 (0)      | 0 (0)     |
| 90                                                       | 0 (0)        | 0 (0)      | 0 (0)     |
| Level II (1 days/week–3 days/week)                       |              |            |           |
| 85                                                       | 50 (66)      | 23 (61)    | 27 (71)   |
| 80                                                       | 9 (12)       | 5 (13)     | 4 (11)    |
| Sports participation in desired sport at the time of study commencement, \(n\) (%) |              |            |           |
| Equal                                                    | 19 (25)      | 10 (26)    | 9 (24)    |
| Reduced                                                  | 29 (38)      | 14 (37)    | 15 (40)   |
| Ceased                                                   | 28 (37)      | 14 (37)    | 14 (37)   |
| Affected side                                            |              |            |           |
| Unilateral, left/right, \(n\) (%)                        | 26 (34) / 18 (24) | 10 (26) / 9 (24) | 16 (42) / 9 (24) |
| Bilateral, \(n\) (%)                                     | 32 (42)      | 19 (50)    | 13 (34)   |
| US-assessment                                            |              |            |           |
| AP thickness, mm ± SD                                    | 8.4 ± 2.3    | 8.2 ± 2.7  | 8.6 ± 2.0 |
| Hypoechoic regions, \(n\) (%)                            | 76 (100)     | 38 (100)   | 38 (100)  |
| Tendon calcifications, \(n\) (%)                         | 20 (26)      | 9 (24)     | 11 (29)   |
| Patellar erosions, \(n\) (%)                             | 24 (32)      | 17 (45)    | 7 (18)    |
| Power Doppler                                            |              |            |           |
| 0: absence of Doppler flow                               | 7 (9)        | 5 (13)     | 2 (5)     |
| 1: Doppler flow posterior to tendon                       | 0 (0)        | 0 (0)      | 0 (0)     |
| 2: 1–2 intratendinous blood vessels                      | 18 (24)      | 12 (32)    | 6 (16)    |
| 3: 3–4 intratendinous blood vessels                      | 7 (9)        | 3 (8)      | 4 (11)    |
| 4: network of blood vessels                              | 44 (58)      | 18 (47)    | 4 (68)    |

**PTLE =** progressive tendon-loading exercise therapy; **EET =** heavy-load eccentric exercise therapy; **SD =** standard deviation; **BMI =** body mass index; **IQR =** interquartile range; **VISA-P =** Victorian Institute of Sports Assessment Questionnaire for patellar tendons; **CSAS =** Cincinnati Sports Activity Scale; **PT =** patellar tendinopathy; \(n\) = number; **US =** ultrasound; **AP =** anterior–posterior. Data are presented as No. (%) unless otherwise specified.
Association between $T_2^*$ in Different Tissue Compartments and Symptom Severity

Adjusted linear regression analysis demonstrated a statistically significant linear association between VISA-P score and $T_2^*$ relaxation times in both degenerative tissue and in the interface between aligned collagen and degenerative tissue (Table 2). Scatter plots of individual associations between mono-exponential $T_2^*$ in specific tissue compartments and VISA-P score are illustrated in Fig. 2.

### TABLE 2. Association Between VISA-P and $T_2^*$ (Multiple Linear Regression Analysis)

|           | Degenerative tissue (0%-30% short $T_2^*$) | Interface (30%-60% short $T_2^*$) | Aligned collagen (60%-100% short $T_2^*$) |
|-----------|------------------------------------------|----------------------------------|------------------------------------------|
| Factor    | $\beta$                                  | 95% CI                           | $P$ value                                | $\beta$                                  | 95% CI                           | $P$ value                                | $\beta$                                  | 95% CI                           | $P$ value                                |
| Age       | 0.008                                    | $-0.125$ to $0.141$              | 0.908                                    | 0.023                                    | $-0.040$ to $0.085$              | 0.472                                    | 0.043                                    | $0.011$ to $0.076$              | <0.05                                    |
| Sex       | 1.460                                    | 0.300–2.620                      | <0.05                                    | 0.422                                    | $-0.121$ to $0.965$              | 0.127                                    | 0.049                                    | $-0.234$ to $0.332$              | 0.732                                    |
| BMI       | 0.015                                    | $-0.175$ to $0.205$              | 0.876                                    | 0.026                                    | $-0.063$ to $0.115$              | 0.561                                    | 0.052                                    | 0.006–0.098                      | <0.05                                    |
| Duration  | <0.001                                   | $-0.004$ to $0.004$              | 0.989                                    | 0.001                                    | $-0.001$ to $0.002$              | 0.482                                    | 0.001                                    | 0.000–0.002                      | <0.05                                    |
| CSAS      | $-0.044$                                 | $-0.119$ to $0.031$              | 0.252                                    | 0.010                                    | $-0.025$ to $-0.006$             | 0.565                                    | 0.006                                    | $-0.012$ to $0.025$             | 0.506                                    |
| VISA-P    | $-0.046$                                 | $-0.075$ to $-0.018$             | <0.05                                    | $-0.019$                                 | $-0.033$ to $-0.006$             | <0.05                                    | $-0.003$                                 | $-0.010$ to $0.004$             | 0.461                                    |

CI = confidence interval; BMI = body mass index; CSAS = Cincinnati Sports Activity Scale; VISA-P = Victorian Institute of Sports Assessment Questionnaire for patellar tendinopathy. Adjusted mean differences that were significant at 0.05 level after Bonferroni correction are in bold.

---

**FIGURE 2:** Association between mono-exponential $T_2^*$ in specific tissue compartments and VISA-P score. Scatter plot of individual $T_2^*$ relaxation times versus symptom severity as scored at baseline and after 12 and 24 weeks with the validated VISA-P questionnaire for patellar tendinopathy. Plots illustrate a significant negative association between mono-exponential $T_2^*$ and VISA-P score in degenerative tissue and interface of the patellar tendon, but not in aligned collagen.
TABLE 3. Unadjusted and Adjusted Change in $T_2^*$ Over Time

| $T_2^*$ subregion | Unadjusted $T_2^*$ (msec ± SD (raw data)) | Adjusted Mean Difference (95% CI), From Baseline* |
|-------------------|------------------------------------------|-----------------------------------------------|
| Degenerative tissue (0%–30% short $T_2^*$) | 14.2 ± 3.2 | 12 weeks: $-0.7 (-1.3$ to $-0.1)$; 24 weeks: $-1.3 (-2.0$ to $-0.6)$ |
| Interface (30%–60% $T_2^*$) | 7.5 ± 1.6 | 12 weeks: $-0.3 (-0.7$ to $-0.2)$; 24 weeks: $-0.6 (-1.1$ to $-0.1)$ |
| Aligned collagen (60%–100% $T_2^*$) | 3.1 ± 0.9 | 12 weeks: $0.1 (-0.2$ to $0.3)$; 24 weeks: $-0.0 (-0.2$ to $0.2)$ |

*The adjusted mean differences were calculated using generalized estimating equations (GEE) with adjustments for the following predefined baseline variables: age, sex, BMI, symptom duration and Cincinnati Sports Activity Scale. Adjusted mean differences that were significant at 0.05 level after Bonferroni correction in bold.

Association between Baseline $T_2^*$ and Change in Symptom Severity

Baseline $T_2^*$ values for all tissue compartments are listed in Table 3. There was no significant association of baseline $T_2^*$ with clinical outcome after 24 weeks of exercise therapy for all of the tissue compartments of the patellar tendon (degenerative tissue [$R^2 = 0.17$, $P = 0.29$], aligned collagen [$R^2 = 0.17$, $P = 0.95$], and the interface compartment [$R^2 = 0.15$, $P = 0.55$]).

Longitudinal UTE-MRI Data and Relation with Clinical Outcome

Among all athletes, a significant decrease in $T_2^*$ was found in the voxels that represented the degenerative tissue of the patellar tendon, from 14 ± 3 msec at baseline to 13 ± 4 msec at 24 weeks (adjusted mean difference [95% CI] = 1 msec [1–2]). The change in $T_2^*$ was not significant at 12 weeks (adjusted mean difference [95% CI] = 1 msec [0–1]), $P = 0.09$. For voxels that represented aligned collagen and voxels that represented the interface between aligned collagen and degenerative tissue, the adjusted mean differences were not statistically significant (Table 3). The interaction term “study arm visit” was not statistically significant for any of the tissue compartments (aligned collagen, $P = 0.42$; interface, $P = 0.49$; degenerative tissue, $P = 0.54$) (Fig. 3). The homogeneity of variance assumption was not violated for all tissue compartments (aligned collagen, $P = 0.59$; interface, $P = 0.17$; degenerative tissue $P = 0.23$). An example of the longitudinal $T_2^*$ change is illustrated in Fig. 4.

The significant $T_2^*$ decrease in the degenerative tissue compartment was significantly associated with the improvement in severity of symptoms as measured with the VISA-P score (main effect, $-1.2$ [95% CI: $-2.0$ to $-0.4$]), Fig. 5. There was no association with clinical outcome for the aligned collagen ($P = 0.77$) and interface ($P = 0.06$) tissue compartments.

Post hoc Sensitivity Analysis of Missing Data

Twenty one of the 195 UTE-MRI acquisitions (11%) were missing (Fig. 1). Sensitivity analyses to assess the influence of missing data showed that the estimated mean VISA-P score improved significantly from 56 points (95% CI: 53–60) at baseline to 69 points (95% CI: 65–73) at 12 weeks and 78 points (95% CI: 74–82) at 24 weeks follow-up among all athletes. After 24 weeks, a significant adjusted mean between-group difference of 11 points (95% CI: 3–18) was found. The $T_2^*$ decrease in degenerative tissue between baseline and 24 weeks follow up remained significant (mean difference, 1 [95% CI: 1–2]). The association with clinical outcome was significant (main effect, $-1.1$ [95% CI: $-1.9$ to $-0.3$]) when...
the most recent preceding $T_2^*$ value was carried forward to substitute all missing values. There were no significant $T_2^*$ changes in voxels that represented aligned collagen (main effect, 0.7 [95% CI: -2.1 to 3.4]; $P = 0.64$) and the voxels that represented the interface (main effect, -1.3 [95% CI: -2.7 to 0.1]; $P = 0.07$) between aligned collagen and degenerative tissue.

### Discussion

We found that $T_2^*$ relaxation times within the degenerative tissue of the patellar tendon were associated with symptom severity in athletes with patellar tendinopathy. There was no predictive value of $T_2^*$ at baseline for the clinical outcome after 24 weeks. Decreasing $T_2^*$ relaxation times were related to a better clinical outcome after 24 weeks using tissue-specific $T_2^*$ analyses.

This randomized controlled trial demonstrated longitudinal changes in $T_2^*$ in patellar tendinopathy using a tissue-specific analysis method based on bi-exponential fitting parameters. The capability of UTE-MRI to detect longitudinal changes had already been demonstrated by others, specifically in healing tendon grafts following anterior cruciate ligament reconstruction, in human cadaveric tendons that were subjected to tensile static loading, and in Achilles tendons of long distance runners.

The small, but significant, decrease in $T_2^*$ relaxation times within the degenerative tissue may demonstrate the patellar tendon’s ability to change structurally in response to exercise therapy. Conservative treatment options focus on structural adaptation of the patellar tendon to progressive loading of the tendon. However, the current evidence is conflicting regarding the effect of exercise therapy on structural adaptation measured with clinically available imaging modalities. The significant association between decreased $T_2^*$ relaxation times and improved clinical
outcome in our study further emphasizes the benefit of strengthening exercises in the treatment of tendinopathy. The hydration state of the degenerative tissue as quantified with $T_2^*$ mapping that was significantly associated with symptom severity was in accordance with a previous study that found an association of glycosaminoglycan content from tendon biopsies with VISA-P score. Subregional $T_2^*$ quantification, facilitating the monitoring of tendon hydration state that is associated with pain when quantified in specific tissue compartments without the need of invasive tendon biopsies, is of great value for future research focusing on clinical outcome after therapeutic interventions.

The mechanism behind the ultrastructural changes that resulted in a $T_2^*$ decrease in the degenerative tissue of the patellar tendon remains unclear. Theoretically, the decrease of long $T_2^*$ components could result from changes in the macromolecular binding state of water, due to an increase or change of the proteoglycan and glycosaminoglycan content within the degenerative tissue. Another possible explanation is that within the degenerative tissue, the voxels contained an increasing proportion of (ultra)short $T_2^*$ components over time, for example, due to newly formed collagen fibers as a response to exercise therapy.

A strength of this study is that we performed a large clinical trial that implemented longitudinal UTE-MRI acquisitions to evaluate $T_2^*$ changes in patients with PT. Other strengths are the advanced methods for image preparation and postprocessing of the UTE-images, including in-house developed linear and nonlinear registration tools for a spatial one-to-one mapping of voxels that were constant over visits from different UTE-acquisitions and the analysis of $T_2^*$ in specific tissue compartments of the patellar tendon. We believe that these methods strongly facilitated the analysis of longitudinal data. After performing sensitivity analyses, our findings were consistent with those from the primary analysis and would lead to similar conclusions about the association between decreased $T_2^*$ in the degenerative tissue of the patellar tendon and improved clinical outcome.

Limitations

We proposed a method to quantify $T_2^*$ in different tissue compartments of the patellar tendon, represented by thresholding the percentage of short $T_2^*$ components voxel-wisely into 0%–30%, 30%–60%, and 60%–100% short $T_2^*$ components. Despite the observation that these subcategories of voxels with similar $T_2^*$ characteristics visually corresponded well to degenerative tissue, interface and aligned collagen, respectively, there is uncertainty if these subcategories really represent these tissues. This primarily affects the construct validity of this method of $T_2^*$ analysis, and is difficult to overcome without direct histologic confirmation of this subcategorization. The chosen thresholds were based on histogram analysis of the frequency distribution of the percentage short $T_2^*$ components in each voxel, which categorized the $T_2^*$ data in three groups, irrespective of what the absolute values were for the short and long components within each voxel. Second, the reliability of the $T_2^*$ quantification is most likely insufficient to detect a clinically relevant difference. From previously published data, we know that the coefficient of repeatability was estimated at 2 msec; however, the change in $T_2^*$ after 24 weeks in all athletes was only 1.3 msec (0.6–2.0). Third, the long acquisition time of our current protocol impedes application in clinical practice. The protocol as implemented was designed to provide an integral sampling of echo times and to provide a high spatial resolution. For this project, this scanning protocol was acceptable, because we did not intend to develop an image protocol that could be used in clinical imaging. For clinical applications, we recommend an abbreviated protocol, for example, as implemented by Fukuda et al. With only six echo times in the short TE range, they managed to observe a decreased $T_2^*$ in a remodeling anterior cruciate ligament graft 6 months post-surgery. Forth, a change in the MR acquisition protocol during the trial was required to optimize SNR for better fitting of $T_2^*$ data, which unfortunately lead to exclusion of 11 patients in the final analyses. Moreover, the unbalanced loss of follow-up between the exercise groups (one in the PTLE group and seven in the EET group), could suggest that the eccentric exercises were less easy to sustain, which seems logical due to the fact that these exercises should be performed with pain. This may also be reflected by the previously reported lower subjective patient satisfaction reported in the control group. Finally, despite the fact that the significant decrease in $T_2^*$ after 24 weeks was associated with clinical improvement in our study participants, it is important to note that the validity of the $T_2^*$ parameters in tendinopathy (with tissue histopathology as reference standard) is currently unknown.

Conclusion

Tissue-specific $T_2^*$ relaxation times identified with 3D-UTE-MRI are associated with symptom severity in athletes with patellar tendinopathy. Decreasing $T_2^*$ relaxation times in the degenerative tissue of the patellar tendon are associated with improved clinical outcome after exercise therapy for patellar tendinopathy, while it is unsuitable as a single predictive measurement at baseline for clinical outcome. While the change in $T_2^*$ was small and the technique has limitations to use in clinical practice, our findings indicate that the hydration state of the patellar tendon is able to change in response to conservative exercise therapy.

Acknowledgments

The authors thank the National Basketball Association (NBA) and GE Healthcare Orthopedics and Sports Medicine Collaboration for providing the research grant and GE Healthcare for providing the ultrasound equipment.

References

1. Van der Worp H, de Poel HJ, Diercks RL, van den Akker-Scheek I, Zwerver J. Jumper’s knee or lander’s knee? A systematic review of the
relation between jump biomechanics and patellar tendinopathy. Int J Sports Med 2014;35:714-722.

2. Scott A, Squier K, Alfredson H, et al. ICON 2019: International scientific tendinopathy symposium consensus: Clinical terminology. Br J Sports Med 2020;54:260-262.

3. Malliaras P, Cook J, Purdam C, Rio E. Patellar tendinopathy: Clinical diagnosis, load management, and advice for challenging case presentations. J Orthop Sport Phys Ther 2015;45:887-899.

4. Tumer J, Malliaras P, Goulis J, Mc AS. It’s disappointing and it’s pretty frustrating, because it feels like it’s something that will never go away. A qualitative study exploring individuals’ beliefs and experiences of Achilles tendinopathy. PLoS One 2020;15:e0233459.

5. Visenti PJ, Khan KM, Cook JL, Kiss ZS, Harcourt PR, Wark JD. The VISA score: An index of severity of symptoms in patients with jumper’s knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group. J Sci Med Sport 1998;1:22-28.

6. Dooking SI, Cook J. How do tendons adapt? Going beyond tissue responses to understand positive adaptation and pathology development: A narrative review. J Musculoskelet Neuronal Interact 2019;19:300-310.

7. Khan KM, Cook JL, Kannus P, Maffulli N, Bonar SF. Time to abandon the “tendinitis” myth. BMJ 2002;324:626-627.

8. Benjamin M, Kaiser E, Milz S. Structure-function relationships in tendons: A review. J Anat 2008;212:211-228.

9. McKee TJ, Perlman G, Morris M, Komarova SV. Extracellular matrix composition of connective tissues: A systematic review and meta-analysis. Sci Rep 2019;9:10542.

10. Khan KM, Bonar F, Desmond PM, et al. Patellar tendinosis (jumper’s knee): Findings at histopathologic examination, US, and MR imaging. Victorian Institute of Sport Tendon Study Group. Radiology 1996;200:821-827.

11. Samiric T, Parkinson J, Ilic MZ, Cook J, Handley CJ. Changes in the composition of the extracellular matrix in patellar tendinopathy. Matrix Biol 2009;28:230-236.

12. Cook JL, Purdam CR. Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 2009;43:409-416.

13. Drew BT, Smith TO, Littlewood C, Sturrock B. Do structural changes (e.g., collagen/matrix) explain the response to therapeutic exercises in tendinopathy: A systematic review. Br J Sports Med 2014;48:966-972.

14. Attia M, Scott A, Carpenter G, et al. Greater glycosaminoglycan content in human patellar tendon biopsies is associated with more pain and a lower VISA score. Br J Sports Med 2014;48:469-475.

15. Krasnoselskaia LV, Fullerton GD, Dodd SJ, Cameron IL. Water in tendon: Orientational analysis of the free induction decay. Magn Reson Med 2005;54:280-288.

16. Privatov PL, Crane-Robinson C. Role of water in the formation of macro-molecular structures. Eur Biophys J 2017;46:203-224.

17. Robson MD, Gatehouse PD, Bydder M, Bydder GM. Magnetic resonance: An introduction to ultrashort TE (UTE) imaging. J Comput Assist Tomogr 2003;27:825-846.

18. Chen J, Grogan SP, Shao H, et al. Evaluation of bound and pore water in cortical bone using ultrashort-TE MRI. NMR Biomed 2015;28:1754-1762.

19. Breda SJ, Poot DHJ, Papp D, et al. Tissue-specific T2* biomarkers in patellar tendinopathy by subregional quantification using 3D ultrashort Echo time MRI. J Magn Reson Imaging 2020;52:420-430.

20. Du J, Diaz E, Carl M, Bae W, Chung CB, Bydder GM. Ultrashort echo time imaging with bicomponent analysis. Magn Reson Med 2012;67:645-649.

21. Juras V, Zbyn S, Pressl C, et al. Regional variations of T2* in healthy and pathologic achilles tendon in vivo at 7 tesla: Preliminary results. Magn Reson Med 2012;68:1607-1613.

22. Kijowski R, Wilson JJ, Liu F. Bicomponent ultrashort echo time T2* analysis for assessment of patients with patellar tendinopathy. J Magn Reson Imaging 2017;46:1441-1447.

23. Barber-Westin SD, Noyes FR. Assessment of sports participation levels following knee injuries. Sports Med 1999;28:1-10.

24. Kulig K, Landel R, Chang Y-J, et al. Patellar tendon morphology in volleyball athletes with and without patellar tendinopathy. Scand J Med Sci Sports 2013;23:e61-e68.

25. Bourke D, Patel S, Flint D. The best physiotherapy exercises for management of patella tendinopathy. National Institute for health and care excellence. Available from: https://bestbets.org/bets/bet.php?id=2873.

26. Breda SJ, Oei EEH, Zwever J, et al. Effectiveness of progressive tendon-loading exercise therapy in patients with patellar tendinopathy: A randomised clinical trial. Br J Sports Med 2021;55:501-509.

27. Carl M, Bydder GM, Du J. UTE imaging with simultaneous water and fat signal suppression using a time-efficient multipoke inversion recovery pulse sequence. Magn Reson Med 2016;76:577-582.

28. Klein S, Staring M, Murphy K, Viergever MA, JPW P. Elastix: A toolbox for intensity-based medical image registration. IEEE Trans Med Imaging 2010;29:196-205.

29. Huizinga W, Poot DHJ, Gujayer J-M, et al. PCA-based groupwise image registration for quantitative MRI. Med Image Anal 2016;29:65-78.

30. Poot DHJ, Klein S. Detecting statistically significant differences in quantitative MRI experiments, applied to diffusion tensor imaging. IEEE Trans Med Imaging 2015;34:1164-1176.

31. Little RJ, D’Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355-1360.

32. Fukuda T, Wengler K, Tank D, et al. Abbreviated quantitative UTE imaging in anterior cruciate ligament reconstruction. BMC Musculoskelet Disord 2019;20:426.

33. Jerban S, Nazaran A, Cheng X, et al. Ultrashort echo time T2* values decrease in tendons with application of static tensile loads. J Biomech 2017;61:160-167.

34. Grosse U, Springer F, Hein T, et al. Influence of physical activity on T1 and T2* relaxation times of healthy achilles tendons at 3T. J Magn Reson Imaging 2015;41:193-201.

35. Bohm S, Mersmann F, Arampatzis A. Human tendon adaptation in response to mechanical loading: A systematic review and meta-analysis of exercise intervention studies on healthy adults. Sport Med - Open 2015;1:7.

36. Huber FA, Guggenberger R. Editorial for “Tissue-Specific T2* Biomarkers in Patellar Tendinopathy by Subregional Quantification Using 3D Ultrashort Echo Time”. J Magn Reson Imaging 2020;52:431-432.

37. Parkinson J, Samiric T, Ilic MZ, Cook J, Handley CJ. Involvement of proteoglycans in tendinopathy. J Musculoskelet Neuronal Interact 2011;11:86-93.

38. Young MA, Cook JL, Purdam CR, Kiss ZS, Alfredson H. Eccentric decline squat protocol offers superior results at 12 months compared with traditional eccentric protocol for patellar tendinopathy in volleyball players. Br J Sports Med 2005;39:102-105.